80R Stock Overview
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AroCell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.024 |
| 52 Week High | kr0.051 |
| 52 Week Low | kr0.017 |
| Beta | 1.1 |
| 1 Month Change | 5.31% |
| 3 Month Change | -20.67% |
| 1 Year Change | -50.42% |
| 3 Year Change | -95.97% |
| 5 Year Change | -91.47% |
| Change since IPO | -94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 80R | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -0.9% | 0.5% |
| 1Y | -50.4% | -11.6% | 1.3% |
Return vs Industry: 80R underperformed the German Life Sciences industry which returned -9% over the past year.
Return vs Market: 80R underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 80R volatility | |
|---|---|
| 80R Average Weekly Movement | 25.2% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 80R's share price has been volatile over the past 3 months.
Volatility Over Time: 80R's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 22 | Anders Hultman | www.arocell.com |
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever.
AroCell AB (publ) Fundamentals Summary
| 80R fundamental statistics | |
|---|---|
| Market cap | €7.30m |
| Earnings (TTM) | -€5.08m |
| Revenue (TTM) | €3.69m |
2.0x
P/S Ratio-1.4x
P/E RatioIs 80R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 80R income statement (TTM) | |
|---|---|
| Revenue | kr43.04m |
| Cost of Revenue | kr45.14m |
| Gross Profit | -kr2.10m |
| Other Expenses | kr57.20m |
| Earnings | -kr59.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -4.88% |
| Net Profit Margin | -137.78% |
| Debt/Equity Ratio | 0% |
How did 80R perform over the long term?
See historical performance and comparison